Celera Diagnostics, Bristol-Myers Squibb in Major Cardiovascular SNP Study | GenomeWeb

NEW YORK, Oct. 7-Celera Diagnostics said today that it had struck a deal with Bristol-Myers Squibb to develop drugs and diagnostics for cardiovascular disease and diabetes.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.